United States - English - NLM (National Library of Medicine)

shionogi inc. - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate 1 mg - for use as adjunctive therapy in the treatment of peptic ulcer. glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. robinul (glycopyrrolate) tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

United States - English - NLM (National Library of Medicine)

casper pharma llc - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - robinul and robinul forte are indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. limitations of use robinul and robinul forte are not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established. robinul and robinul forte are contraindicated in: • patients at risk for anticholinergic toxicity due to an underlying medical condition, including:       o glaucoma [see warnings and precautions (5.1) ]       o obstructive uropathies, including prostatic hypertrophy       o mechanical obstructive diseases of the gastrointestinal tract (e.g., pyloroduodenal stenosis, strictures) [see warnings and precautions (5.2) ]       o gastrointestinal motility disorders (e.g., achalasia, paralytic ileus, intestinal atony) [see  warnings and precautions (5.3) ]       o bleeding gastrointestinal ulcer       o active inflammatory or infectious colitis which can lead to toxic megaco

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (united states) - glycopyrronium bromide - oral tablet - 1mg

Canada - English - Health Canada

wyeth-ayerst canada inc. - glycopyrrolate - tablet - 1mg - glycopyrrolate 1mg - antimuscarinics antispasmodics

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - glycopyrronium bromide 0.2 mg/ml; glycopyrronium bromide 0.2 mg/ml - solution for injection - 0.2 mg/ml - active: glycopyrronium bromide 0.2 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection active: glycopyrronium bromide 0.2 mg/ml excipient: benzyl alcohol hydrochloric acid water for injection - robinul is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes during induction of anaesthesia and intubation when indicated. robinul injectable may be used intraoperatively to counteract drug-induced or vagal traction reflexes with the associated arrhythmias. glycopyrrolate protects against the peripheral muscarinic effects (e.g. bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarising muscle relaxants.

Ireland - English - HPRA (Health Products Regulatory Authority)

a.h. robins company limited - glycopyrronium bromide - tablets - 2.0 milligram

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate 0.2 mg in 1 ml - robinul injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. when indicated, robinul injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. for use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated. known hypersensitivity to glycopyrrolate or any of its inactive ingredients. in addition, in the management of peptic ulcer patients, because of the longer duration

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - glycopyrronium bromide, quantity: 0.2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; hydrochloric acid - 1.as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents. 2.as a preoperative or intraoperative antimuscarinic to attenuate or prevent intraoperative bradycardia associated with the use of suxa-methonium or due to cardiac vagal reflexes. 3.to protect against the peripheral muscarinic actions (eg. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by nondepolarising muscle relaxants.

Canada - English - Health Canada

wyeth-ayerst canada inc. - glycopyrrolate - tablet - 2mg - glycopyrrolate 2mg - antimuscarinics antispasmodics

Canada - English - Health Canada

ayerst laboratories - glycopyrrolate - tablet - 2mg - glycopyrrolate 2mg - antimuscarinics antispasmodics